Israel’s cannabis regulator drops the word “medical” from most of its rules
Sixteen changes to production and distribution rules • Drafted in January 2024, due to take effect that year

In January 2024 the Ministry of Health was putting the final wording on updates to Israel's medical-cannabis procedures, as part of an «enabling regulation» reform in the industry. The main points of that reform were published in August 2023, and it was due to take effect from April 2024 onward.
The draft of the new procedures, which had recently been sent to operators in the industry for last comments, presents the changes in a track-changes format, so it is possible to see not only what was added, but also what was deleted and removed from the procedure.
Most of the changes in the procedure were immediate and were due to take effect in the following weeks once the wording was completed, but the procedure on displaying active compounds was due to be implemented from April 2024, and the new category procedure from July 2024.
These were the 16 most prominent changes:
Narrowing the use of the term «medical» cannabis. The word «medical», which had officially accompanied cannabis in Ministry of Health and IMCA documents since about 2009, was removed from most of the places where it appeared in the official procedure, and it was also expected to be removed from product packs, so that only the term «cannabis product» would appear, without the addition «medical». In some headings it is still written that the cannabis is «for medical use».
Under the new procedure, the Israel Medical Cannabis Agency (IMCA, known in Hebrew as יק״ר, the medical cannabis unit at the Ministry of Health) officially becomes a «division» in the ministry, to be called «the Division for Supervision and Regulation of the Medical Cannabis System (IMCA)». Above the head of IMCA, Yuval Landschaft, policy would be supervised by Ran Ridnik, head of the Economics, Regulation and Innovation Division. The names of the authors of the previous procedure (Boaz Elbo, Rachel Shimonovitz, Eli Marom, Yoram Rubinstein, David Schwartz and others) were to be removed, and replaced by the names of new office holders (Shulamit Gorelik, Ela Aharon, Tal Lavi and others).
Alongside the term «cannabis product» a new term was added that had not existed before: «export product». The purpose of this new definition is to carry out a 2021 government decision stating that, for the first time, Israeli cannabis companies would be allowed to export cannabis products abroad even if they are prohibited for use in Israel. At the time, only cannabis flower and cannabis oil could be produced and marketed in Israel. An «export product» could also include, for example, vape pens, extracts (hashish, dab and the like), tablets, pessaries and other forms prohibited for marketing in Israel. In that case, producers would be required to make them on a production line separate from products intended for the domestic market.
A new term, «excellent manufacturer», was also added, meaning a licensed manufacturer that has passed two consecutive routine inspections successfully. A manufacturer holding that title would receive regulatory relief, for example fewer inspections, independence in setting product expiry, fewer tests at the plant's exit points, and more.
Alongside «farm», «plant», «pharmacy» and the other links in the cannabis production chain, a link was added for the first time named «post-harvest cannabis treatment facility». Until then, the post-harvest facility, where trimming, drying and curing of the flowers are carried out, up to bulk packaging and transfer for packing as a finished product at the plants, was part of a «cultivation farm». It would now become a «link» that could also operate separately from other links, and provide trimming, curing and bulk-packaging services for others.
A product-recall procedure was set out in an orderly way for the first time, and would be carried out according to the Pharmacy Division's procedure for medical preparations.
As Cannabis Magazine first reported in July 2023, displaying the percentage of active compounds (THC, CBD, CBN and so on) would be prohibited both on product packs and on company websites. Until then there had been a duty to display the percentage of active compounds on a sticker on every pack, and also on a dedicated page on the companies' websites. Exposure of the data on the pack would now not only cease to be a duty, but would be forbidden. Manufacturers would still be required to carry out those tests and keep them, so that Ministry of Health representatives could access them for inspection if needed.
There would no longer be a duty to display on the pack the name of the growing farm and the other licence holders for cultivation, processing and packing who are responsible for the product, nor the harvest month of the cannabis, as had been required until then, but only the name of the «manufacturer», that is the name of the plant alone. Companies that wanted to could still note those names, as well as the names of the source cultivars («the genetics»). It should be noted that the procedure that required displaying the growing farm's name and the harvest date had not in any case been implemented in practice by the vast majority of companies.
Product packs would no longer be done according to «IMCA instructions to be issued from time to time», as until then, but as required in the Pharmacy Division's packing-label procedure. The structure of one inner pack (pouch or jar) and one outer pack (carton) would be kept, but the design would change so that illustrations which in some cases now decorate the entire pack could appear only on up to one sixth (15%) of the size of the pack's main face.
As in a procedure that had already entered into force at the end of 2022, it would not be possible to use the names of foods or sweets for cannabis products (such as «candy», «cake» or «cherry», for example), and from now it would also not be possible to use illustrations of commercial characters (such as «Niro», «Gadi Wilcherski» or other well-known figures). The wording would not mislead as to the product's properties, would not have connotations from the world of children and youth, and would not encourage consumption.
It would be permitted to display pictures or illustrations of fruit and leaves in order to indicate flavours. There would be a duty to specify the types of terpenes in the product and the type of carrier oil in cannabis oil products (for example, «olive oil»). Existing details such as category (T/C), batch number and expiry date, logos, warning signs, barcodes and so on would continue to appear as usual, but, as noted, the exact THC and CBD percentages would no longer appear.
The Ministry of Health leaves in the procedure the existing instruction under which driving is prohibited while using cannabis, or while active cannabinoids or their metabolites are present in the patient's blood, something that according to the Ministry of Health «can take a number of days after the last use».
The procedure notes the new sub-procedure, «Procedure 108», which sets out the instructions for filing applications to license new forms of administration. For the first time it would be possible, after research and a demonstration of safety, to market in Israel products that are not flower or oils, «if they are approved by the Ministry of Health». That is how, many hope, vape pens and extracts might be allowed, and/or the development of products for the CBD market such as cosmetics, food supplements, products for animals and the like. This was not expected to happen soon, but only after such studies. Holders of cultivation sites, post-harvest facilities or plants would be able to carry out the research on the premises of their existing licensed facilities, in accordance with Helsinki Committee procedures and the like.
New categories: cannabis products would continue to be divided into three main dose categories (high THC, balanced, and high CBD), but the T/C sub-categories would change. In the high-THC group, instead of T10/C2, T15/C3 and T20/C4, the categories would be T10/C3, T12/C4, T15/C5, T18/C6 and T22/C7. In the high-CBD group, instead of T0/C24, T1/C20, T3/C15 and T5/C10, the categories would be T0/C26, T1/C22, T3/C18, T3/C15, T3/C12 and T5/C10. In the balanced group, alongside T3/C3, T5/C5 and T10/C10, which already existed, two new categories would appear: T12/C12 and T14/C14. Several gaps were found in this new table; further details were published separately in the magazine at the time.
On the other hand, a clause that may make pharmacy deliveries easier is that if the patient or a proxy is not at home at the time of delivery, the cannabis would be returned to the pharmacy and would not be required to be sent for destruction, as had been required until then, something that had made it very hard for pharmacies to provide delivery services under the procedures.
The Ministry of Health cancels the duty of «corporate separation», that is the requirement that every link in the production chain be registered in the name of a different company, even if all the companies are ultimately under one ownership. That duty had led to high accountancy costs for several different tax files and the like, and would now be cancelled. In addition, the condition that work in the cannabis field was limited to ages 25 and up is cancelled. From now, any Israeli citizen would be able to file an application to work in the cannabis field, and to receive it if the requirements were met, with no age limit.
As noted, alongside those changes, whose core is in the production and distribution stages, further changes were due to take effect on the treatment side, for example cancelling the duty to exhaust prior narcotic drug treatment («last-line treatment») as a condition for receiving a cannabis-use licence, a move to a «cannabis on a doctor's prescription» model without the need for a licence for about 10% of patients at the first stage, and more.
What later coverage shows (added 20.11.2026)
This article is a snapshot of the January 2024 draft, not a live description of every rule in force today. The magazine has not published a later item that walks through all 16 changes one by one. Later coverage does show that some of the main planks moved forward: an updated category table was issued on 20 February 2024 and was due to apply to new products from 1 July 2024, and from 1 April 2025 pharmacies were no longer to sell flower or oils outside those categories (articles 179959 and 138485). In August 2026 the magazine described a major 2024 visual change to packs as already in place, while reporting that IMCA was examining a possible further, Canadian-style model (article 285779). In the same month it reported that the harvest date still does not appear on the finished pack sold to patients (article 285766). A Health Ministry letter in October 2026 tightened advertising language (article 288767). None of that is a finding that every clause in the January 2024 draft took effect unchanged.